Share Your Research, Maximize Your Social Impacts
THE USE OF TOCILIZUMAB IN THE TREATMENT OF A SYSTEMIC VARIANT OF JUVENILE IDIOPATHIC ARTHRITIS
Journal: Pediatric Bulletin of the South Ural (Vol.1, No. 1)Publication Date: 2021-06-13
Authors : Aksenov A.V. Ivanovskaya E.A.;
Page : 88-91
Keywords : systemic arthritis; Тocilizumab; children;
Source : Download Find it from : Google Scholar
Abstract
To date, in the arsenal of drugs used in the treatment of juvenile idiopathic arthritis with systemic onset, there is a drug Тocilizumab, which is a recombinant humanized monoclonal antibody to the IL-6 receptor. The article presents a clinical case of the use of Тocilizumab in a child with a systemic variant of juvenile idiopathic arthritis with ineffective treatment with glucocorticosteroids and Мethotrexate.
Other Latest Articles
- THE BORROWING OF FOREIGN VOCABULARY IN RUSSIAN MEDICAL ORGANIZATIONS
- BASIC CONCEPTS, GROUPS AND INDICATIONS FOR PALLIATIVE CARE FOR CHILDREN AT HOME AND IN BOARDING INSTITUTIONS
- HOMOCYSTEINEMIA – A MARKER OF MULTIFACTORIAL DISEASES OF CHILDHOOD
- PROCESSES OF MOLECULAR OOGENESIS AT THE STAGES OF EXTRACORPORAL FERTILIZATION
- SICKLE CELL ANEMIA IN THE REFLECTION OF PHILATELIUM AND ON MEMORABLE MEDALS
Last modified: 2021-07-08 07:01:38